Zhang et al. used the PDTX model to test the antitumor efficacy of gefitinib on non-small cell lung cancer patients with EGFR, KRAS and FGFR gene mutations, and results were consistent with previous clinical trials (11). Here, KRAS is linked to non-small cell lung carcinoma.